Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Christophe Willekens et al.|Blood|2017Cited by 1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Eytan M. Stein et al.|New England Journal of Medicine|2018Cited by 1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret O’Donnell, Ndiya Ogba, Martin S. Tallman et al.|Journal of the National Comprehensive Cancer Network|2017Cited by 655
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M. Stein, Martin S. Tallman, Guillermo Garcia‐Manero et al.|Blood|2018Cited by 457
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P. Shah, Kristina M. Gregory, Ravi Bhatia et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 116